Change over period
From:
To:
Zoom:
- 1Y
- 3Y
- 5Y
- 10Y
- 15Y
- 20Y
- Max
CEO | Mr. Timothy P. Noyes M.B.A. |
IPO Date | June 30, 2021 |
Location | United States |
Headquarters | 930 Winter Street, Waltham, MA, United States, 02116 |
Employees | 51 |
Sector | Healthcare |
Industry | Biotechnology |
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
NA
NA
NA
NA
StockViz Staff
September 20, 2024
Any question? Send us an email